Oncology Central is hosting a free 2-day online educational symposium, chaired by Professor Angus Dalgleish (St George’s, University of London) aimed at delivering oncology professionals key updates in this field. This online symposium will be CME-accredited.
Browsing: Taxonomy > Immunotherapy
This article provides a immunotherapy perspective of Ipilimumab, a CTLA-4-targeted monoclonal antibody, reviewing drug mechanism, blockade, combination therapies and future prospectives.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
Utilizing granzyme B, researchers have uncovered a novel method for detecting tumors response to immunotherapy therapy earlier.
Discuss the history of the development of intralesional therapies, current effective therapies and the future direction of these injectable therapies.
Research has suggested that a signaling lymphocytic activation molecule contributes to differences in immunotherapy efficacy in hematopoietic tumors.
Survival gains reported in a phase I trial of a cytomegalovirus pp65-targeted vaccine for glioblastoma.
A group of researchers may have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.
Lydia Makaroff of the European Cancer Patient Coalition (ECPC, Brussels, Belgium) speaks with Oncology Central about the goals and upcoming projects for the ECPC in 2017.